Shares of Mesoblast Limited (MESO) touched a new 52-week high of $12.70 yesterday, as the company awaits the FDA decision on Ryoncil in the proposed indication of pediatric steroid-refractory acute graft versus host disease.
Ryoncil, also known as Remestemcel-L, comprises of culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.